Advancements in Immune Checkpoint Inhibitor-Based Systemic Therapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with a particularly high incidence in China. The disease is often diagnosed at an advanced stage, limiting treatment options and leading to poor outcomes. The IMbrave150 trial marked a significant breakthrough by establishing the combination of atezolizumab and bevacizumab as a first-line treatment for advanced HCC, showcasing the potential of ICI-based systemic therapy.

ICI-based systemic therapy encompasses various approaches, including ICI monotherapy, dual-immunotherapy, and combinations of ICI with TKI, VEGF inhibitors, or chemotherapy. Studies have shown that dual-immunotherapy offers higher response rates and better efficacy compared to ICI monotherapy, despite the increased toxicity associated with higher doses of anti-CTLA-4. Notably, the combination of Tremelimumab and Durvalumab has demonstrated a favorable benefit-risk profile.

A case study of a 60-year-old man with advanced HCC and inferior vena cava tumor thrombus illustrates the potential of ICI plus TKI therapy. After failing to respond to multiple postoperative therapies, the patient achieved partial remission following treatment with Lenvatinib plus Pembrolizumab, highlighting the regimen's effectiveness as a rescue therapy for HCC patients resistant to other treatments.

Despite these advancements, the treatment of HCC remains challenging, especially for patients with underlying uncompensated cirrhosis. The combination of ICI with TKI presents a promising option, offering better patient adherence and drug tolerance. Ongoing clinical trials, such as KEYNOTE-524/Study116 and RESCUE, continue to explore the efficacy and safety of these combination therapies, with early results showing encouraging outcomes.

The future of HCC treatment lies in further understanding the mechanisms of different combination therapies, identifying biomarkers for ICI response, and conducting more clinical trials to evaluate the use of ICI and ICI combinations in patients with concomitant cirrhosis. These efforts will be crucial in advancing personalized therapy and improving outcomes for HCC patients.